Literature DB >> 4133588

Relation of measles virus to encephalitogenic factor with reference to the aetiopathogenesis of multiple sclerosis.

J R McDermott, E J Field, E A Caspary.   

Abstract

A combination of affinity chromatography with the macrophage electrophoretic migration (MEM) test has been used to study the antigenic similarities between encephalitogenic factor (EF) and measles virus. These have determinant(s) sufficiently closely related to account for the elevated level of circulating antibody to measles in multiple sclerosis.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4133588      PMCID： PMC494642          DOI： 10.1136/jnnp.37.3.282

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  21 in total

1.  Specific separation of cells on affinity columns.

Authors:  P Truffa-Bachi; L Wofsy
Journal:  Proc Natl Acad Sci U S A       Date:  1970-07       Impact factor: 11.205

2.  The derivatization of cross-linked polyacrylamide beads. Controlled introduction of functional groups for the preparation of special-purpose, biochemical adsorbents.

Authors:  J K Inman; H M Dintzis
Journal:  Biochemistry       Date:  1969-10       Impact factor: 3.162

3.  Lymphocyte transformation in vitro measured by tritiated thymidine uptake. I. Lymphocyte culture techniques.

Authors:  D Hughes; E A Caspary
Journal:  Int Arch Allergy Appl Immunol       Date:  1970

4.  Sensitization of blood lymphocytes to possible antigens in neurological disease.

Authors:  E A Caspary; E J Field
Journal:  Eur Neurol       Date:  1970       Impact factor: 1.710

5.  Demonstration of sensitized lymphocytes in blood.

Authors:  E J Field; E A Caspary
Journal:  J Clin Pathol       Date:  1971-03       Impact factor: 3.411

6.  Lymphocyte sensitisation: an in-vitro test for cancer?

Authors:  E J Field; E A Caspary
Journal:  Lancet       Date:  1970-12-26       Impact factor: 79.321

7.  Antibodies to measles antigen, control antigen, and monkey kidney antigen. Studies in patients with multiple sclerosis and other neurological diseases and normal healthy individuals.

Authors:  E A Caspary; M E Chambers; E J Field
Journal:  Neurology       Date:  1969-11       Impact factor: 9.910

8.  Response of human blood lymphocytes to tuberculin PPD in tissue culture.

Authors:  A S Coulson; D G Chalmers
Journal:  Immunology       Date:  1967-04       Impact factor: 7.397

9.  Specific lymphocyte sensitization in cancer: is there a common antigen in human malignant neoplasia?

Authors:  E A Caspary; E J Field
Journal:  Br Med J       Date:  1971-06-12

10.  Cell separation on antigen-coated columns. Elimination of high rate antibody-forming cells and immunological memory cells.

Authors:  H Wigzell; B Andersson
Journal:  J Exp Med       Date:  1969-01-01       Impact factor: 14.307
View more
  6 in total

1.  Relationship between measles HI titers and an MS susceptibility gene.

Authors:  R W Haile; B R Visscher; R Detels; N L Valdiviezo; J L Sever; D L Madden
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

2.  Scrapie: a review of its relation to human disease and ageing.

Authors:  E J Field
Journal:  J Med Genet       Date:  1976-12       Impact factor: 6.318

3.  Measles antibodies and kappa-lambda light chain distribution in immunoglobulins of patients affected with multiple sclerosis.

Authors:  F Bollengier; A Mahler
Journal:  J Neurol       Date:  1979-03-22       Impact factor: 4.849

4.  Subacute sclerosing panencephalitis and multiple sclerosis: in vitro measles immunity and sensitization to myelin basic protein.

Authors:  W Sheremata; A Sazant; G Watters
Journal:  Can Med Assoc J       Date:  1978-03-04       Impact factor: 8.262

Review 5.  Herpesviruses--a rationale for antiviral treatment in multiple sclerosis.

Authors:  T Bergström
Journal:  Antiviral Res       Date:  1999-02       Impact factor: 5.970

Review 6.  Viruses, virulence and pathogenicity.

Authors:  J Hibbs; N S Young
Journal:  Baillieres Clin Haematol       Date:  1995-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.